- Analog of Cisplatin with reduced nephrotoxicity. Antineoplastic
- anticancer drugs
- Antipyretic Analgesics and NSAIDs
Carboplatin was discovered at Michigan State University and developed at the Institute of Cancer Research in London.
Bristol-Myers Squibb gained Food and Drug Administration (FDA) approval for carboplatin, under the brand name
Paraplatin, in March 1989. Starting in October 2004, generic versions of the drug became available.
Carboplatin is a chemotherapy drug used against some forms of cancer mainly ovarian carcinoma, lung, head and neck cancers. It was introduced in the late 1980s and has since gained popularity in clinical treatment due to its vastly reduced side-effects compared to its parent compound cisplatin. Cisplatin and carboplatin, as well as oxaliplatin,
are classified as DNA alkylating agents.
Antitumor agent that forms platinum-DNA adducts. Causes intra- and interstrand DNA crosslinks
blocking DNA replication and transcription. Enhances radiation-induced single-strand DNA
breakage and displays lower nephrotoxicity than analog cisplatin (cis-Diaminodichloroplatinum ).
Stability:Stable. Incompatible with strong oxidizing agents.
CarboplatinCAS No.: 41575-94-4
CisplatinCAS No: 15663-27-1
We are carboplatin price supplier, for better price, pls inquiry us now!